Literature DB >> 12853581

Do myelin-directed antibodies predict multiple sclerosis?

Jack P Antel1, Amit Bar-Or.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853581     DOI: 10.1056/NEJMp030098

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

Review 2.  T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.

Authors:  Itay Raphael; Saisha Nalawade; Todd N Eagar; Thomas G Forsthuber
Journal:  Cytokine       Date:  2014-10-30       Impact factor: 3.861

Review 3.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

4.  High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics.

Authors:  Allysa Lui; Janet Chong; Eoin Flanagan; Aaron W Abrams; Kristen M Krysko; Burak Arikan; Carla Francisco; Alice Rutatangwa; Emmanuelle Waubant; Amin Ziaei
Journal:  Mult Scler Relat Disord       Date:  2021-09-04       Impact factor: 4.339

Review 5.  [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].

Authors:  C Kleinschnitz; S G Meuth; B C Kieseier; H Wiendl
Journal:  Nervenarzt       Date:  2007-08       Impact factor: 1.214

6.  Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis.

Authors:  Til Menge; Patrice H Lalive; H Christian von Büdingen; Claude P Genain
Journal:  J Neuroinflammation       Date:  2011-11-17       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.